dc.contributor.author |
Nemes Karolina |
|
dc.contributor.author |
Sebestyén Anna |
|
dc.contributor.author |
Márk Ágnes |
|
dc.contributor.author |
Hajdu Melinda |
|
dc.contributor.author |
Kenessey István |
|
dc.contributor.author |
Sticz Tamás Béla |
|
dc.contributor.author |
Nagy E |
|
dc.contributor.author |
Barna Gábor |
|
dc.contributor.author |
Váradi Zsófia |
|
dc.contributor.author |
Kovács Gábor |
|
dc.contributor.author |
Kopper László |
|
dc.contributor.author |
Csóka Monika |
|
dc.date.accessioned |
2014-03-28T08:37:16Z |
|
dc.date.available |
2014-03-28T08:37:16Z |
|
dc.date.issued |
2013 |
|
dc.identifier.citation |
pagination=e59335, 11 pages;
journalVolume=8;
journalIssueNumber=4;
journalTitle=PLOS ONE; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/65 |
|
dc.identifier.uri |
doi:10.1371/journal.pone.0059335 |
|
dc.description.abstract |
Modern treatment strategies have improved the prognosis of childhood ALL; however, treatment still fails in 25-30% of patients. Further improvement of treatment may depend on the development of targeted therapies. mTOR kinase, a central mediator of several signaling pathways, has recently attracted remarkable attention as a potential target in pediatric ALL. However, limited data exists about the activity of mTOR. In the present study, the amount of mTOR activity dependent phospho-proteins was characterized by ELISA in human leukemia cell lines and in lymphoblasts from childhood ALL patients (n = 49). Expression was measured before and during chemotherapy and at relapses. Leukemia cell lines exhibited increased mTOR activity, indicated by phospho-S6 ribosomal protein (p-S6) and phosphorylated eukaryotic initiation factor 4E binding protein (p-4EBP1). Elevated p-4EBP1 protein levels were detected in ALL samples at diagnosis; efficacy of chemotherapy was followed by the decrease of mTOR activity dependent protein phosphorylation. Optical density (OD) for p-4EBP1 (ELISA) was significantly higher in patients with poor prognosis at diagnosis, and in the samples of relapsed patients. Our results suggest that measuring mTOR activity related phospho-proteins such as p-4EBP1 by ELISA may help to identify patients with poor prognosis before treatment, and to detect early relapses. Determining mTOR activity in leukemic cells may also be a useful tool for selecting patients who may benefit from future mTOR inhibitor treatments. |
hu |
dc.relation.ispartof |
urn:issn:1932-6203 |
|
dc.title |
Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). |
hu |
dc.type |
Journal Article |
hu |
dc.date.updated |
2014-03-28T08:34:09Z |
|
dc.identifier.mtmt |
2338608 |
|
dc.identifier.wos |
000318840100017 |
|
dc.identifier.pubmed |
23573198 |
|
dc.contributor.department |
SE/ÁOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet |
|
dc.contributor.department |
SE/ÁOK/I/IISZPI/MTA-SE Molekuláris Onkológia Kutatócsoport |
|
dc.contributor.department |
SE/ÁOK/K/II. Sz. Gyermekgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|
dc.mtmt.swordnote |
Nemes K and Sebestyen A contributed equally to this work. |
|